Relationship of hepatitis B virus infection to the recurrence of hepatocellular carcinoma after direct acting antivirals

Abstract

Recently, two conflicting articles about recurrence of hepatocellular carcinoma (HCC) after direct acting antivirals (DAA) against hepatitis C virus (HCV) were published. We investigated the relationship between DAA and HCC recurrence. Eligible patients were (1) history of HCC and treated curatively with interventions, and (2) interferon-free DAA therapy was initiated after eradication of HCC. We analyzed contributing factor for HCC recurrence. Ten out of 23 participants (43%) encountered recurrence of HCC. Age, sex, diabetes mellitus, fibrosis score, chemistry, and alpha-fetoprotein did not differ between patients with recurrence and patients without recurrence. The patients with recurrence had significantly higher values of antibody to hepatitis B core antigen (anti-HBc) than the patients without recurrence, 6.06±3.75 vs. 0.91±2.43 (p=0.0019). The relative risk of HCC recurrence comparing anti-HBc positive to negative was 5.2 (95% confidence interval 1.40 to 19.32). Odds ratio was 22.0 (95% confidence interval 2.5 to 191.1). We conclude that anti-HBc positivity was a strong contributing factor for HCC recurrence after DAA therapy.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Reig M, Marino Z, Perello C, et al. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy. J Hepatol. 2016;65:719–26.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Pol S. Lack of evidence of an effect of direct acting antivirals on the recurrence of hepatocellular carcinoma: the ANRS collaborative study group on hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol. 2016;65:734–40.

  3. 3.

    Adachi S, Shibuya A, Miura Y, Takeuchi A, Nakazawa T, Saigenji K. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus. Scand J Gastroenterol. 2008;43:849–56.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Ikeda K, Marusawa H, Osaki Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med. 2007;146:649–56.

    Article  PubMed  Google Scholar 

  5. 5.

    Nan X, Shi S, Yu C, Zhuang H. Meta-analysis of the association between anti-HBc seropositivity and a poor prognosis of chronic HCV infection. Hepatol Res. 2010;40:1176–87.

    Article  PubMed  Google Scholar 

  6. 6.

    Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996;2:1104–8.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Chu CM, Yeh CT, Liaw YF. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J Clin Microbiol. 1998;36:2084–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. 8.

    De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016;78:27–30.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    D’Ambrosio R, Della Corte C, Colombo M. Hepatocellular carcinoma in patients with a sustained response to anti-hepatitis C therapy. Int J Mol Sci. 2015;16:19698–712.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported, in part, by the Research Program on Hepatitis research from the Japan Agency for Medical Research and Development, AMED, and a grant for Practical Research on Hepatitis B from the Ministry of Health, Labour, and Welfare of Japan, and a grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Keiji Matsui.

Ethics declarations

Conflict of interest

HS, KM, SI, TF, MN, KT, HT, HN, MN, and TW declare that they have no conflict of interest.

Ethical approval

Not required, because this was a retrospective analysis of the past clinical records.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Shimizu, H., Matsui, K., Iwabuchi, S. et al. Relationship of hepatitis B virus infection to the recurrence of hepatocellular carcinoma after direct acting antivirals. Indian J Gastroenterol 36, 235–238 (2017). https://doi.org/10.1007/s12664-017-0755-3

Download citation

Keywords

  • Direct acting antivirals
  • HBc antibody
  • Hepatitis B virus
  • Hepatocellular carcinoma
  • Recurrence
  • Recurrence of HCC